(Q58376703)

1

0 references

Kenji Ikeda

3

0 references

Elke Verhey

4

0 references

Hiroshi Suzuki

5

0 references

Solko W. Schalm

Scandinavian Journal of Gastroenterology

6

0 references

publication date

January 2006

0 references

published in

0 references

volume

41

0 references

issue

9

0 references

page(s)

1087-1094

0 references

cites work

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Glycyrrhizin inhibits TNF-induced, but not Fas-mediated, apoptosis in the human hepatoblastoma line HepG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Licorice for hepatitis C: yum-yum or just ho-hum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

A structural approach to selection bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

Understanding the divergent data on postmenopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

G-estimation of causal effects: isolated systolic hypertension and cardiovascular death in the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520600641365